Department of Neuroscience and Center for Advanced Pain Studies, University of Texas at Dallas, 800 W Campbell Rd, Richardson, TX, 75080, USA.
Sci Rep. 2023 Mar 22;13(1):4670. doi: 10.1038/s41598-023-31603-x.
There is increasing evidence of sex differences in underlying mechanisms causing pain in preclinical models, and in clinical populations. There are also important disconnects between clinical pain populations and the way preclinical pain studies are conducted. For instance, osteoarthritis pain more frequently affects women, but most preclinical studies have been conducted using males in animal models. The most widely used painkillers, nonsteroidal anti-inflammatory drugs (NSAIDs), act on the prostaglandin pathway by inhibiting cyclooxygenase (COX) enzymes. The purpose of this study was to analyze the preclinical and clinical literature on the role of prostaglandins and COX in inflammation and pain. We aimed to specifically identify studies that used both sexes and investigate whether any sex-differences in the action of prostaglandins and COX inhibition had been reported, either in clinical or preclinical studies. We conducted a PubMed search and identified 369 preclinical studies and 100 clinical studies that matched our inclusion/exclusion criteria. Our analysis shows that only 17% of preclinical studies on prostaglandins used both sexes and, out of those, only 19% analyzed or reported data separated by sex. In contrast, 79% of the clinical studies analyzed used both sexes. However, only 6% of those reported data separated by sex. Interestingly, 14 out of 15 preclinical studies and 5 out of 6 clinical studies that analyzed data separated by sex have identified sex-differences. This builds on the increasing evidence of sex-differences in prostaglandin signaling and the importance of sex as a biological variable in data analysis. The preclinical literature identifies a sex difference in prostaglandin D synthase (PTGDS) expression where it is higher in female than in male rodents in the nervous system. We experimentally validated that PTGDS expression is higher in female human dorsal root ganglia (DRG) neurons recovered from organ donors. Our semi-systematic literature review reveals a need for continued inclusivity of both male and female animals in prostaglandins studies and data analysis separated by sex in preclinical and clinical studies. Our finding of sex-differences in neuronal PTGDS expression in humans exemplifies the need for a more comprehensive understanding of how the prostaglandin system functions in the DRG in rodents and humans.
越来越多的证据表明,在临床人群中,潜在的疼痛机制存在性别差异,而在临床人群中,也存在着临床疼痛人群与临床人群之间的重要脱节。例如,骨关节炎疼痛更常发生在女性身上,但大多数临床前疼痛研究都是在动物模型中使用雄性进行的。应用最广泛的止痛药非甾体抗炎药(NSAIDs)通过抑制环氧化酶(COX)酶作用于前列腺素途径。本研究的目的是分析前列腺素和 COX 在炎症和疼痛中的临床前和临床文献。我们旨在专门确定使用两性的研究,并调查在临床或临床前研究中是否有报道前列腺素和 COX 抑制作用的任何性别差异。我们进行了 PubMed 搜索,并确定了 369 项符合我们纳入/排除标准的临床前研究和 100 项临床研究。我们的分析表明,只有 17%的前列腺素临床前研究使用了两性,而在这些研究中,只有 19%的研究分别分析或报告了性别数据。相比之下,79%的临床研究分析使用了两性。然而,只有 6%的研究报告了性别数据。有趣的是,14 项临床前研究和 5 项临床研究分别分析了性别数据,这些研究都发现了性别差异。这是基于前列腺素信号传递中性别差异的不断增加的证据,以及在数据分析中性别作为一个生物学变量的重要性。临床前文献确定了前列腺素 D 合酶(PTGDS)表达中的性别差异,即雌性啮齿动物神经系统中的表达高于雄性。我们通过实验验证了从器官捐献者中恢复的女性人类背根神经节(DRG)神经元中 PTGDS 表达更高。我们的半系统文献综述揭示了需要继续在前列腺素研究中纳入雄性和雌性动物,并在临床前和临床研究中分别进行性别分析。我们在人类中发现神经元 PTGDS 表达的性别差异,这表明需要更全面地了解前列腺素系统在 DRG 中如何在啮齿动物和人类中发挥作用。